Blood gas analysers and monitors

Immediate bedside results increase sales

In 2006 blood gas analysers and monitors earned manufacturers revenues of around US$360.5 million, and revenues could reach US$470 million in 2013, according to a new market report from Frost & Sullivan (F&S).

Siemens Medical Solutions RapidPoint® 400 Series
Siemens Medical Solutions RapidPoint® 400 Series

‘Laboratory tests that used to take around 30 minutes for the result to be obtained are now a thing of the past; currently manufactured point of care devices yield immediate answers,’ the report’s author, research analyst C R Hema Varshika, explained. That instant bedside capability, along with a rising patient population is, she believes, the cause of a notable sales boost. 


The main challenges for manufacturers include each country having its own purchasing system, which will only change when countries adopt uniform laws. The author attributes other problems to the high levels of brand consciousness among hospitals and ‘intense competition from local participants’. This, Ms Farshika suggests, can be overcome through innovative products and effective marketing strategies. ‘Proactive marketing of technologically advanced and user-friendly products will lead to a rise in market share,’ she then predicts.


F&S points out that this analysis - ‘The European Blood Gas Analysers and Monitors Market’ (M00B – 56) - is part of its Patient Monitoring Subscription, which includes research on: Remote Patient Monitoring and the Strategic Analysis of the European Neurological Monitoring Market.

For a virtual brochure, e-mail Radhika Menon Theodore - Corporate Communications at rmtheodore@frost.com, giving your name, company name, title, phone number, e-address, city, state, and country.

(http://www.patientmonitoring.frost.com)

08.03.2007

More on the subject:

Related articles

Photo

News • iCTG for resource-constrained settings

Mobile fetal heart monitoring linked to fewer newborn deaths

Introducing mobile iCTG dramatically improves the detection of fetal heart rate abnormalities and strengthens perinatal outcomes - even in resource-constrained environments, a new study shows.

Photo

News • CAR-T and BITEs

At-home monitoring safely cuts hospital time after T-cell redirecting therapy

After T-cell redirecting therapies, patients are typically hospitalized for several days to watch for side effects. New research shows that these patients can safely be monitored at home.

Photo

News • Improved long-term glucose

Telemedicine monitoring helps patients with type 1 diabetes

Type 1 diabetes is demanding for patients. A new study shows the benefits of a systematic, intensive treatment with remote monitoring of glucose levels and weekly healthcare contact.

Related products

Subscribe to Newsletter